Helena Polena

Dr. Helena Polena


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2017 in British Journal of Cancer
Verified
Journal Article
Open access
PRPauline Rochefort
Pauline Rochefort
SCSylvie CHABAUD
Sylvie CHABAUD
JPJean-Yves Pierga
Jean-Yves Pierga
OTOlivier Trédan
Olivier Trédan
EBEtienne Brain
Etienne Brain
TBThomas BACHELOT
Thomas BACHELOT
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

30 November 2021 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
HPHelena Polena
Helena Polena
MCMarlène CHAVAGNAC
Marlène CHAVAGNAC
Laurent MiseryLaurent Misery
Laurent Misery
MSMichèle Sayag
Michèle Sayag
The assessment of sensitive skin syndrome, characterized by subjective unpleasant sensations, remains a challenge, since there is no international consensus on the best diagnostic tools. This study evaluated the combination of the Burden of Sensitive Skin (BoSS) questionnaire and the current perception threshold as diagnostic tools for sensitive skin syndrome, and the relationship between BoSS and the subjects’ smoking status, phototype and skin type. A total of 100 women completed the BoSS questionnaire, and current perception threshold was measured on the face. The BoSS score was significantly higher in the self-reported sensitive skin group compared with the non-sensitive skin group (25.61 vs 14.05; p < 0.001), and in non-smokers vs smokers (23.00 vs 18.37; p < 0.05). In addition, the current perception threshold values were similar between the sensitive and non-sensitive groups. These results suggest that BoSS is a better diagnostic tool for sensitive skin syndrome than the current perception threshold, and that smokers less frequently have sensitive skin than do non-smokers.

6 October 2022 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
HPHelena Polena
Helena Polena
MCMarlène CHAVAGNAC
Marlène CHAVAGNAC
MSMichèle Sayag
Michèle Sayag
Purpose: Xerosis and pruritus are common chronic dermatological disorders among dialysis and diabetic patients that are frequently underdiagnosed or neglected, which can impact the quality of life of these patients. This study aimed to evaluate the efficacy and safety of a specific dermo-cosmetic product in the treatment of dry skin and pruritus associated with dialysis and diabetes. Patients and Methods: Twenty-nine dialysis patients (mean age 62 years) and 40 diabetic patients (mean age 57 years, 88% type 2) were included in two different single-center open-label uncontrolled clinical trials. All patients presented skin dryness according to the Scaling Roughness Redness and Cracks (SRRC) scale, and pruritus and/or insomnia. They applied the dermo-cosmetic product Medi-Secure Atoderm Xereane (NAOS, Laboratoire Bioderma) once or twice a day. The clinical efficacy (SRRC, pruritus, and insomnia), the skin-related quality of life (Dermatological Life Quality Index, DLQI), and the subjective efficacy were assessed at the inclusion visit and after 28 days of product application, as well as the safety. Results: After 28 days of application, the product significantly reduced the SRRC global score of 83% (0.9± 0.8 vs 5.1± 1.2) and 66% (1.4± 1.2 vs 4.2± 0.5), pruritus intensity of 76% (1.1± 1.3 vs 4.6± 2.1) and 78% (0.9± 1.7 vs 4.2± 2.6), and insomnia intensity of 61% (0.9± 1.3 vs 2.4± 2.3) and 82% (0.9± 1.7 vs 4.8± 2.7) in dialysis and diabetic patients, respectively. Furthermore, the product’s application led to an improvement of the skin-related quality of life of 50% (5.4 vs 2.7; p< 0.0001) in dialysis patients and 71% (6.6 vs 1.9; p< 0.0001) in diabetic patients at D28. In addition, the product was greatly appreciated by all patients for its soothing, comforting, repairing, nourishing, and hydrating effects and was very well tolerated by the entire panels. Conclusion: This specific dermo-cosmetic product significantly reduces skin dryness, pruritus, and insomnia in dialysis and diabetic patients, thereby greatly improves their skin-related quality of life. By managing and avoiding bothersome symptoms associated with their disease or treatment, this ecobiological dermo-cosmetic can prevent serious complications that constitute a substantial burden on their daily life.

1 December 2017 in Joint Bone Spine
Verified
Journal Article
Closed access
CBChristopher Banse
Christopher Banse
HPHelena Polena
Helena Polena
BSBarry Stidder
Barry Stidder
AKAbir Khalil-Mgharbel
Abir Khalil-Mgharbel
EHEstelle Houivet
Estelle Houivet
IVIsabelle Vilgrain
Isabelle Vilgrain

27 September 2025 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
HPHelena Polena
Helena Polena
CQCatherine Queille‐Roussel
Catherine Queille‐Roussel
CGChristelle Graizeau
Christelle Graizeau
LDLuc Duteil
Luc Duteil
MSMichèle Sayag
Michèle Sayag
TPThierry PASSERON
Thierry PASSERON

18 September 2024 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
HPHelena Polena
Helena Polena
AFArnaud Fontbonne
Arnaud Fontbonne
EAElise Abric
Elise Abric
GLGuillaume Lecerf
Guillaume Lecerf
MCMarlène CHAVAGNAC
Marlène CHAVAGNAC
MSMichèle Sayag
Michèle Sayag
Objective: Environmental factors are important in the generation or aggravation of sensitive skin syndrome (SSS). Creams can be useful for patients with SSS, particularly when triggering factors cannot be avoided. Several clinical studies have investigated the safety and efficacy of specific creams in patients with SSS, but the majority were assessed with a single type of triggering factor and were non‐comparative. Therefore, this study's aim was to investigate, the benefit of a specific dermo‐cosmetic product in response to physical and chemical factors in subjects with SSS. Methods: Three clinical studies were performed on subjects presenting SSS. The physical impact was assessed in a stripping test, and in a randomized intra‐individual study with a newly developed heat–cold stress model. To assess chemical factors, a capsaicin test on the nasolabial fold was performed. Results: The product significantly reduced the increase in skin microcirculation caused by stripping after 30 min versus. The untreated condition (45.8% vs. 62.0%; p < 0.01). Immediately and at D28, the product induced a significant increase in skin hydration even after a heat–cold stress, while the overall score of unpleasant symptoms significantly decreased compared with the control (8.1 vs. 10.7 and 3.7 vs. 8.0, respectively; p < 0.01). Regarding chemical factors, a significant difference in the sensation intensity ( p < 0.001) was observed after capsaicin stress, also in terms of the sensation duration due to the product application versus the control (192 s vs. 403 s; p < 0.001). Conclusion: These studies show that topical application of a dermo‐cosmetic product can prevent unpleasant symptoms and improve the skin state in SSS exposed to physical and chemical triggering factors.